satyamstechsci
Member
- Bài viết
- 241
- Được Like
- 0
Market Outlook
The India Active Pharmaceutical Ingredients (API) Market is poised for significant growth over the coming years, driven by the country’s established position as a global leader in pharmaceutical manufacturing and its increasing focus on self-reliance in API production. Valued at USD 13.60 billion in 2024, the market is anticipated to reach USD 21.99 billion by 2030, reflecting a robust compound annual growth rate (CAGR) of 8.30%. This expansion is underpinned by rising domestic demand for affordable healthcare solutions, a growing export market, and government initiatives aimed at reducing dependency on imported APIs, particularly from China. India’s cost-effective production capabilities, coupled with a skilled workforce, position it as a key player in meeting global pharmaceutical needs, especially for generic drugs.
Looking ahead, the market is expected to benefit from advancements in biotechnology and a shift toward high-value, complex APIs, aligning with global trends in personalized medicine and chronic disease management. The increasing prevalence of lifestyle-related illnesses, such as diabetes and cardiovascular diseases, further fuels demand for APIs tailored to these therapeutic areas. However, challenges such as stringent regulatory requirements and environmental compliance costs may temper growth. Despite these hurdles, India’s strategic investments in research and development (R&D), along with supportive policies like the Production Linked Incentive (PLI) scheme, are likely to sustain its upward trajectory, reinforcing its role as the "pharmacy of the world."
Browse market data Figures and spread through 120 Pages and an in-depth TOC on " India Active Pharmaceutical Ingredients Market” - https://www.techsciresearch.com/report/india-active-pharmaceutical-ingredients-market/7277.html
Market Driver Analysis
The India Active Pharmaceutical Ingredients Market is propelled by several key drivers that enhance its growth potential. A primary factor is the rising incidence of chronic diseases across the country. According to the International Diabetes Federation (IDF), over 74 million individuals in India were diagnosed with diabetes in 2021, a number projected to increase significantly by the end of the decade. This surge in chronic conditions, including cardiovascular diseases and cancer, drives demand for APIs used in both generic and innovative drugs. Additionally, the aging population contributes to this trend, with the United Nations estimating that India’s elderly population (aged 60 and above) will reach 194 million by 2030, necessitating greater pharmaceutical intervention.
Government initiatives play a pivotal role in market expansion. The "Make in India" campaign and the PLI scheme, launched with an outlay of over INR 6,940 crore (approximately USD 951 million) from FY21 to FY30, aim to boost domestic API production and reduce reliance on imports, which previously accounted for nearly 70% of India’s API supply, predominantly from China. This push for self-sufficiency has attracted investments from both domestic and international players, with over 50 bulk drug parks and manufacturing units approved under the scheme by 2023. Furthermore, India’s competitive manufacturing costs—often 30-40% lower than those in Western markets—enhance its appeal as a global API supplier.
The growing export market is another significant driver. India accounts for approximately 30% of global generic medicine exports, with shipments to over 200 countries. In FY23, pharmaceutical exports reached USD 25.4 billion, according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), reflecting strong international demand for cost-effective APIs. The increasing trend of outsourcing API production to India by multinational corporations, leveraging the country’s skilled labor pool of over 50,000 science and technology graduates annually, further accelerates growth. Additionally, advancements in R&D, supported by collaborations between industry and academia, enable the development of complex APIs, meeting the needs of emerging therapeutic areas like oncology and biologics, thus solidifying India’s position in the global pharmaceutical landscape.
Segmentations
The India Active Pharmaceutical Ingredients Market can be segmented based on multiple criteria, reflecting its diverse applications and production methodologies. Below are the key segmentations:
By Method of Synthesis:
Key Players and Analysis
The India Active Pharmaceutical Ingredients Market is shaped by a mix of domestic giants and global players, each contributing to its competitive landscape. Below is a list of key players followed by an analysis:
Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=7277
LinkedIn - https://www.linkedin.com/pulse/india-active-pharmaceutical-ingredients-market-ogvme/
The India Active Pharmaceutical Ingredients (API) Market is poised for significant growth over the coming years, driven by the country’s established position as a global leader in pharmaceutical manufacturing and its increasing focus on self-reliance in API production. Valued at USD 13.60 billion in 2024, the market is anticipated to reach USD 21.99 billion by 2030, reflecting a robust compound annual growth rate (CAGR) of 8.30%. This expansion is underpinned by rising domestic demand for affordable healthcare solutions, a growing export market, and government initiatives aimed at reducing dependency on imported APIs, particularly from China. India’s cost-effective production capabilities, coupled with a skilled workforce, position it as a key player in meeting global pharmaceutical needs, especially for generic drugs.
Looking ahead, the market is expected to benefit from advancements in biotechnology and a shift toward high-value, complex APIs, aligning with global trends in personalized medicine and chronic disease management. The increasing prevalence of lifestyle-related illnesses, such as diabetes and cardiovascular diseases, further fuels demand for APIs tailored to these therapeutic areas. However, challenges such as stringent regulatory requirements and environmental compliance costs may temper growth. Despite these hurdles, India’s strategic investments in research and development (R&D), along with supportive policies like the Production Linked Incentive (PLI) scheme, are likely to sustain its upward trajectory, reinforcing its role as the "pharmacy of the world."
Browse market data Figures and spread through 120 Pages and an in-depth TOC on " India Active Pharmaceutical Ingredients Market” - https://www.techsciresearch.com/report/india-active-pharmaceutical-ingredients-market/7277.html
Market Driver Analysis
The India Active Pharmaceutical Ingredients Market is propelled by several key drivers that enhance its growth potential. A primary factor is the rising incidence of chronic diseases across the country. According to the International Diabetes Federation (IDF), over 74 million individuals in India were diagnosed with diabetes in 2021, a number projected to increase significantly by the end of the decade. This surge in chronic conditions, including cardiovascular diseases and cancer, drives demand for APIs used in both generic and innovative drugs. Additionally, the aging population contributes to this trend, with the United Nations estimating that India’s elderly population (aged 60 and above) will reach 194 million by 2030, necessitating greater pharmaceutical intervention.
Government initiatives play a pivotal role in market expansion. The "Make in India" campaign and the PLI scheme, launched with an outlay of over INR 6,940 crore (approximately USD 951 million) from FY21 to FY30, aim to boost domestic API production and reduce reliance on imports, which previously accounted for nearly 70% of India’s API supply, predominantly from China. This push for self-sufficiency has attracted investments from both domestic and international players, with over 50 bulk drug parks and manufacturing units approved under the scheme by 2023. Furthermore, India’s competitive manufacturing costs—often 30-40% lower than those in Western markets—enhance its appeal as a global API supplier.
The growing export market is another significant driver. India accounts for approximately 30% of global generic medicine exports, with shipments to over 200 countries. In FY23, pharmaceutical exports reached USD 25.4 billion, according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), reflecting strong international demand for cost-effective APIs. The increasing trend of outsourcing API production to India by multinational corporations, leveraging the country’s skilled labor pool of over 50,000 science and technology graduates annually, further accelerates growth. Additionally, advancements in R&D, supported by collaborations between industry and academia, enable the development of complex APIs, meeting the needs of emerging therapeutic areas like oncology and biologics, thus solidifying India’s position in the global pharmaceutical landscape.
Segmentations
The India Active Pharmaceutical Ingredients Market can be segmented based on multiple criteria, reflecting its diverse applications and production methodologies. Below are the key segmentations:
By Method of Synthesis:
- Synthetic: This segment dominates due to the ease of production and widespread use in generic drugs, leveraging readily available raw materials and established chemical processes.
- Biological: Gaining traction with the rise of biologics and biosimilars, this segment focuses on complex molecules like proteins and antibodies, driven by advancements in biotechnology.
- Contract Manufacturing Organizations (CMOs): This segment is expanding as companies outsource API production to reduce costs, with CMOs handling over 40% of generic API output in 2024.
- In-house Manufacturing: Preferred by large firms for quality control and cost efficiency, this segment accounts for a significant share, supported by investments in captive facilities.
- Cardiovascular Diseases: A leading segment due to high disease prevalence, with over 20.5 million CVD-related deaths globally in 2021, per the World Heart Report.
- Anti-diabetic Drugs: Growing rapidly with India’s diabetes burden, catering to millions of patients annually.
- Oncology Drugs: Expanding due to rising cancer cases, with a focus on high-potency APIs.
- Neurological Disorders: Addressing conditions like Alzheimer’s, with increasing demand for specialized APIs.
- Musculoskeletal Disorders: Serving an aging population with pain management solutions.
- Others: Includes respiratory, infectious diseases, and niche therapeutic areas.
- Generics: The largest segment, driven by India’s dominance in global generic exports, accounting for 30% of the market.
- Innovator: Focused on novel APIs, this segment is growing with increased R&D investments and patent expirations.
Key Players and Analysis
The India Active Pharmaceutical Ingredients Market is shaped by a mix of domestic giants and global players, each contributing to its competitive landscape. Below is a list of key players followed by an analysis:
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Dr. Reddy’s Laboratories Ltd.
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Lupin Limited
- Aurobindo Pharma Limited
- Aarti Drugs Ltd.
- IOL Chemicals and Pharmaceuticals Limited
- GSK plc
Download Free Sample Report - https://www.techsciresearch.com/sample-report.aspx?cid=7277
LinkedIn - https://www.linkedin.com/pulse/india-active-pharmaceutical-ingredients-market-ogvme/
Bài viết liên quan
